BioSpace News Archive

Nurix Therapeutics Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the first quarter ended February 28, 2021 and provided a corporate update.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its First Quarter 2021 results on Wednesday, April 28, 2021 after the Mexican Market (BMV) close.

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2021 after market close on Tuesday, May 4, 2021 at 4:30 PM Eastern Time

Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, plans to announce financial results for the second quarter fiscal year 2021 after market close on Monday, May 10, 2021.

Endo International plc (NASDAQ: ENDP) today announced that Phase 3 data evaluating Qwo® (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women was published in Dermatologic Surgery, the official journal of the American Society for Dermatologic Surgery

Bruker Corporation announced preliminary revenue for the first quarter ended March 31, 2021 in a range of $549 - $554 million, representing reported revenue growth of approximately 30% to 31%, compared to the first quarter of 2020.

A team of top scientists from the University of Bristol have announced the formation of a new biotech company that is developing ground-breaking and newly patented potential treatments for Coronavirus.

Kaiser Permanente study showed that a history of being consistently active was strongly associated with a reduced risk of hospitalization, ICU admission, and death in those with COVID-19

Biopsies have remarkably advanced the molecular medicine in general and oncology in particular. Technological strides in the devices used for biopsies have considerably improved the molecular characterization of cancers.

Dr. Reddy’s Laboratories Ltd. announced that it has received the permission from the Drug Controller General of India to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act.